Date | Title | Description | |
---|---|---|---|
22 Jun 2021 | On significant placements in financial instruments | Bestinver announces the beginning of an accelerated book build process of up to a 3% of the share capital of Laboratorios Rovi, S.A. | Download |
29 Apr 2021 | On business and financial situation | The Company informs about the increase of its fill-finish capacity for the manufacture of Moderna’s COVID-19 vaccine outside the United States. | Download |
12 Apr 2021 | On business and financial situation | The Company releases the press release related to its participation in the manufacture of the active substance of Moderna’s COVID-19 vaccine. | Download |
02 Mar 2021 | On business and financial situation | The Company releases an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
02 Mar 2021 | On business and financial situation | The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
Pages
Date | Title | Description | |
---|---|---|---|
27 Jul 2022 | On business and financial situation | The Company releases the first half 2022 financial results presentation | Download |
04 Jul 2022 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the second quarter of 2022 | Download |
30 Jun 2022 | Other relevant information | The Company informs about the dividends payment | Download |
16 Jun 2022 | Other relevant information | The Company has agreed to execute the capital reduction approved by the 2022 Ordinary General Meeting to amortize the shares acquired in the framework of the own shares repurchase programs | Download |
14 Jun 2022 | Announcement of general shareholders’ meeting | ROVI releases the information related to its General Shareholders Meeting | Download |
Pages
Date | Title | Description | |
---|---|---|---|
10 May 2018 | Otros sobre negocio y situación financiera | Update pivotal PRISMA-3 study of DORIA® (Risperidone ISM®) | Download |
25 Apr 2018 | Información sobre resultados | ROVI releases the press release related to the 2018 first quarter financial results | Download |
25 Apr 2018 | Convocatorias y acuerdos de Juntas y Asambleas generales | ROVI informs about the call for the 2018 Ordinary General Shareholders Meeting | Download |
25 Apr 2018 | Información sobre resultados | ROVI releases the 2018 first quarter results presentation | Download |
04 Apr 2018 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the first quarter of 2018 | Download |